Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Oxurion NV Major Shareholding Notification 2025

Jun 18, 2025

3987_mrq_2025-06-18_513f2baf-15be-4899-bbe6-82b3fa15c30f.pdf

Major Shareholding Notification

Open in viewer

Opens in your device viewer

Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC

Leuven, BELGIUM – June 18, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows:

Oxurion received a transparency notification on June 16, 2025, from Atlas Special Opportunities II, LLC indicating that as of June 10, 2025, it held 1,548,410 shares of the then outstanding 8,496,303 shares, and therefore crossed under the threshold (20%) by virtue of the selling of voting securities.

About Oxurion

Oxurion NV (Euronext Brussels: OXUR) is a biopharmaceutical group in transition, combining therapeutic innovation with technologies applied to clinical research. Through its rapidly expanding technology division, Oxurion is building integrated expertise around clinical data, with the ambition to accelerate, secure, and transform the processes involved in developing new treatments. The Group's headquarters are based in Leuven, Belgium. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forwardlooking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

For further information please contact:

Oxurion NV Pascal Ghoson Chief Executive Officer [email protected]

________

  1. Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.

ANNEX 1

FSMA FINANCIAL SERVICES AND
MARKETS AUTHORITY
Form TR-1 BE
PART I
Transparency notification
1) Status of the notification
Final
2) Issuer
Identification number 0881-620-924 Name OXURION
3) Reason for the notification
Acquisition or disposal of voting securities or voting rights
4) Notification by
A person that notifies alone
5) Persons subject to the notification requirement
Name Address (for legal entitles)
Atlas Special Opportunities II LLC 2500 Westchester Avenue, Suite 401, Purchase, NY 10577
6) Persons that dispose of voting rights (only to be filled in it art. 7 of the Law applies)
Name Address (for legal entitles)
Please continue entering the information in part if concerning the
persons referred to In Sections 5 and 6
Part II
7) Date on which the threshold is crossed
10/06/2025 (DD/MM/YYYYY)
8) Threshold that is crossed (In %)
20
r the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10
9) Denominator
8,496,303
Please enter the denominator before filling in the data
10) Notified details
A) Voting rights Previous notification After the transaction
# of voting rights # of voting rights Not linked to the % of voting rights
Not linked to the
B) Equivalent financial Instruments After the transaction
Holders of equivalent
financial Instruments
Type of financial Instrument Expiration data Exercise period or
date
# of voting rights
that may be
acquired if the
Instrument Is
exercised
% of voting rights Settlement
+
TOTAL 0 0.00%
10 The torals will be updated once you have clicked on «CALCULATE>
TOTAL (A & B) # of voting rights % of voting rights
CALCULATE 1,548,410 18.22%

11) Full chain of controlled undertakings through which the holding is effectively held, it applicable

12) In case of proxy voting for only one GM

Holder will cease to hold /
will hold again
voting rights as of

13) Additional information

On 4 Ine 2026 (wiellement dele of Jure 2025). Atas Special Cruicil Station N, as result thich shamillian in the Frazer ( 1,26, Fra bere F 2,265, Fra bere ( 1,26, 1,4 and er 1

Done at New York
On 12/06/2025 (DD/MM/YYYYY)
Name & capacity Patrick Vance, Proxyhoider Patrick Vance
Signature
CONSULTIONAL

For security reasons, the unsigned form in xlsx format should
be transmitted to [email protected]. You can do this manually
OR if you have MS Outlook at your disposal via th

In addition, a signed copy in PDE format should also be transmitted.